The role of lupus anticoagulant and triple marker positivity as risk factors for rethrombosis in patients with primary antiphospholipid syndrome

Clinical and Experimental Rheumatology

Volumn 31, Issue 3, 2013, Pages 382-388

  Hernandez Molina G ^a   Espericueta Arriola, G ^a   Cabral, A R ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Antiphospholipid syndrome; Lupus anticogulant; Oral anticoagulation; Rethrombosis; Triple marker

Indexed keywords

ANTICOAGULANT AGENT; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LA ANTIBODY; LUPUS ANTICOAGULANT;

ADULT; AGE; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOSIS;

ADULT; ANTIBODIES, ANTICARDIOLIPIN; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; KAPLAN-MEIER ESTIMATE; LUPUS COAGULATION INHIBITOR; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOSIS;

EID: 84878370351     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. KHAMASHTA MA, CUADRADO MJ, MUJIC F, TAUB NA, HUNT BJ, HUGHES GRV: The management of thrombosis in the antiphospholipid syndrome. N Engl J Med 1995; 332: 993-7.
2. DERKSEN RHWM, DE GROOT PG, KATER L, NIEUWENHUIS HK: Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant therapy. Ann Rheum Dis 1993; 52: 689-92.
3. ALARCÓN-SEGOVIA D, BOFFA MC, BRANCH DW et al.: Prophylaxis of the antiphospholipid syndrome: a consensus report. Lupus 2003; 12: 499-503.
4. CROWTHER MA, GINSBERG JS, JULIAN J et al.: A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-8.
5. RUIZ-IRASTORZA G, KHAMASHTA MA, HUNT BJ, ESCUDERO A, CUADRADO MJ, HUGHES GR: Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. Arch Intern Med 2002; 162: 1164-9.
6. PENGO V, RUFFATTI A, LEGNANI C et al.: Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010; 8: 237-42.
7. MIYAKIS S, LOCKSHIN MD, ATSUMI T et al.: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
8. RUFFATTI A, TONELLO M, VISENTIN MS et al.: Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology (Oxford) 2011; 50: 1684-9.
9. PENGO V, RUFFATTI A, LEGNANI C et al.: Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 2011; 118: 4714-8.
10. GOVONI M, BOMBARDIERI S, BORTOLUZZI A et al.: Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profileexist? A large multicentre retrospective cross-sectional study on 959 Italian patients. Rheumatology (Oxford) 2012; 51: 157-68.
11. ERKAN D, YAZICI Y, PETERSON MG, SAMMARITANO L, LOCKSHIN MD: A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 2002; 41: 924-9.
12. GIRON-GONZALEZ JA, GARCIA DEL RIO E, RODRIGUEZ C, RODRIGUEZ-MARTORELL J, SERRANO A: Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol 2004; 31: 1560-7.
13. DANOWSKI A, DE AZEVEDO MN, DE SOUZA PAPI JA, PETRI M: Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol 2009; 36: 1195-9.
14. RUFFATTI A, ROSS TD, CIPRIAN M et al.: Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis 2011; 70: 1083-6.
15. REGGIA R, ZIGLIOLI T, ANDREOLI L et al.: Primary anti-phospholipid syndrome: any role for serum complement levels in predicting pregnancy complications? Rheumatology (Oxford) 2012 Aug 25. [Epub ahead of print].
16. 2-glycoprotein-I than with antiphospholipid antibodies. J Rheumatol 1995; 22: 1899-906.
17. BRANDT JT, TRIPLETT DA, ALVING B, SCHARRER I: Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 1995; 74: 1185-90.
18. HOCHBERG MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
19. ALARCÓN-SEGOVIA D, DELEZÉ M, ORIA CV et al.: Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine 1989; 68: 353- 65.
20. ALARCÓN-SEGOVIA D, PÉREZ-VÁZQUEZ ME, VILLA AR, DRENKARD C, CABIEDES J: Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Semin Arthritis Rheum 1992; 21: 275-86.
21. ERKAN D, LOCKSHIN M: New approaches for managing antiphospholipid syndrome. Nat Clin Pract Rheumatol 2009; 5: 160-70.
22. PENGO V: Classification of patients with antiphospholipid syndrome into risk categories: an evolving process. [letter]. Thromb Haemost 2006; 96: 855-6.
23. TARR T, LAKOS G, BHATTOA HP, SHOENFELD Y, SZEGEDI G, KISS E: Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients. Lupus 2007; 16: 39-45.
24. GALLI M, LUCIANI D, BERTOLINI G, BARBUI T: Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101: 1827-32.
25. 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003; 102: 2717-23.
26. DE GROOT PG, LUTTERS B, DERKSEN RHWM, LISMAN T, MEIJERS JCM, ROSENDAAL FR: Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. Journal of thrombosis and haemostasis: JTH 2005; 3: 1993-17.
27. DE LAAT B, PENGO V, PABINGER I et al.: The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 2009; 7: 1767-73.
28. ERKAN D, HARRISON M, LEVY R et al.: Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibodypositive individuals. Arthritis Rheum 2007; 56: 2382-91.
29. CERVERA R, KHAMASHTA MA, SHOENFELD Y et al.: Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2009; 68: 1428-32.
30. LES I, RUIZ-IRASTORZA G, KHAMASHTA MA: Intensity and duration of anticoagulation therapy in antiphospholipid syndrome. Semin Thromb Hemost 2012; 38: 339-47.
31. PENGO V, RUIZ-IRASTORZA G, DENAS G, ANDREOLI L, KHAMASHTA M, TINCANI A: High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: 'PROS' and 'CONS'. Autoimmun Rev 2012; 8: 577-80.